View the latest news and SEC filings
Scroll to
One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation
Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44 th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m.
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
April 28, 2023 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
April 28, 2023 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
April 28, 2023 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
April 28, 2023 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
April 28, 2023 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
April 25, 2023 |
An amendment to the SC 13G filing |
SC 13G/A |
Other |
|
|
April 20, 2023 |
A statement of beneficial ownership of common stock by certain persons |
SC 13G |
Other |
|
|
March 21, 2023 |
Official notification to shareholders of matters to be brought to a vote (“Proxy”) |
DEF 14A |
Proxy Filings |
|
|
March 21, 2023 |
An annual report to security holders |
ARS |
Annual Filings |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
